RxDoctor Payments Data

Paul Speckart, MD

Internal Medicine · San Diego, CANPI 1447346192

Payments from drug & device makers

$317in general payments, 2019–2025

Across 16 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ascensia Diabetes Care US Inc.$27
  • Astellas Pharma US Inc$27
  • Lilly USA, LLC$26
  • AbbVie$24
  • Radius Health, Inc.$23
  • Abbott$23
  • plus $168 from 9 others

What the payments were for

  • Food & beverage$317100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$317 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$111,838
Medicare patients
288
Services billed
2,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide111$123,993
TrulicityDulaglutide35$46,594
EliquisApixaban28$42,466
XareltoRivaroxaban27$42,384
JardianceEmpagliflozin35$33,052
Tresiba Flextouch U-200Insulin Degludec23$24,451
ProliaDenosumab14$23,598
FarxigaDapagliflozin Propanediol15$18,841
OzempicSemaglutide13$11,594
SynthroidLevothyroxine Sodium83$9,674
Ezetimibe206$9,078
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$7,672
PremarinEstrogens, Conjugated13$7,605
Rosuvastatin Calcium316$6,097
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$4,478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$26$170,587146 claims
PfizerEliquis, Premarin$20$50,07241 claims
AmgenProlia$17$23,59814 claims
Novo NordiskOzempic$17$11,59413 claims
AbbVieSynthroid$24$9,67483 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →